Below are the most recent publications written about "Polyamines" by people in Profiles.
-
Dryja P, Fisher C, Woster PM, Bartee E. Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291.
-
Urban-Wójciuk Z, Graham A, Barker K, Kwok C, Sbirkov Y, Howell L, Campbell J, Woster PM, Poon E, Petrie K, Chesler L. The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme. Cancer Gene Ther. 2022 07; 29(7):940-950.
-
El Bissati K, Redel H, Ting LM, Lykins JD, McPhillie MJ, Upadhya R, Woster PM, Yarlett N, Kim K, Weiss LM. Novel Synthetic Polyamines Have Potent Antimalarial Activities in vitro and in vivo by Decreasing Intracellular Spermidine and Spermine Concentrations. Front Cell Infect Microbiol. 2019; 9:9.
-
Murray Stewart T, Dunston TT, Woster PM, Casero RA. Polyamine catabolism and oxidative damage. J Biol Chem. 2018 11 30; 293(48):18736-18745.
-
Murray-Stewart T, Dunworth M, Lui Y, Giardiello FM, Woster PM, Casero RA. Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies. PLoS One. 2018; 13(8):e0202677.
-
Murray-Stewart TR, Woster PM, Casero RA. Targeting polyamine metabolism for cancer therapy and prevention. Biochem J. 2016 10 01; 473(19):2937-53.
-
Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One. 2015; 10(5):e0127246.
-
Verlinden BK, de Beer M, Pachaiyappan B, Besaans E, Andayi WA, Reader J, Niemand J, van Biljon R, Guy K, Egan T, Woster PM, Birkholtz LM. Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes against multiple lifecycle forms of Plasmodium falciparum parasites. Bioorg Med Chem. 2015 Aug 15; 23(16):5131-43.
-
Saraswathy M, Knight GT, Pilla S, Ashton RS, Gong S. Multifunctional drug nanocarriers formed by cRGD-conjugated ßCD-PAMAM-PEG for targeted cancer therapy. Colloids Surf B Biointerfaces. 2015 Feb 01; 126:590-597.
-
Murray-Stewart T, Hanigan CL, Woster PM, Marton LJ, Casero RA. Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. Mol Cancer Ther. 2013 Oct; 12(10):2088-99.